NCT02224937View on ClinicalTrials.gov

MELATOX: Evaluation of Percutaneous Dissolvement of Melatonin When Used as Sunscreen; a Randomized, Placebo Controlled, Double-blind Crossover Study on Healthy Volunteers.

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

December 31, 2013

Primary Completion Date

February 28, 2014

Conditions
Solar Skin Damage
Interventions
DRUG

Melatonin

DRUG

Placebo

Trial Locations (1)

2730

Herlev Sygehus, Herlev

All Listed Sponsors
lead

Zealand University Hospital

OTHER

NCT02224937 - MELATOX: Evaluation of Percutaneous Dissolvement of Melatonin When Used as Sunscreen; a Randomized, Placebo Controlled, Double-blind Crossover Study on Healthy Volunteers. | Biotech Hunter | Biotech Hunter